Cartesian Therapeutics Inc. (RNAC) — Cash Flow-to-Debt Ratio
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2026, meaning its operating cash flow of $-22.14 Million could theoretically repay 0% of its total liabilities ($436.51 Million) in one year. Explore Cartesian Therapeutics Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cartesian Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Cartesian Therapeutics Inc. across 12 annual periods. Also explore Cartesian Therapeutics Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cartesian Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Cartesian Therapeutics Inc.. For market capitalisation and broader financial context, see RNAC market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.17x | $-73.94 Million | $422.65 Million | ▼ -226.5% |
| 2024 | -0.05x | $-23.67 Million | $441.82 Million | ▲ +21.9% |
| 2023 | -0.07x | $-51.16 Million | $745.23 Million | ▲ +84.4% |
| 2022 | -0.44x | $-31.63 Million | $72.06 Million | ▲ +0.1% |
| 2021 | -0.44x | $-60.38 Million | $137.36 Million | ▼ -331.2% |
| 2020 | 0.19x | $34.88 Million | $183.44 Million | ▲ +133.7% |
| 2019 | -0.56x | $-51.44 Million | $91.17 Million | ▲ +52.4% |
| 2018 | -1.19x | $-59.16 Million | $49.90 Million | ▼ -12.3% |
| 2017 | -1.06x | $-52.04 Million | $49.29 Million | ▼ -84.2% |
| 2016 | -0.57x | $-19.68 Million | $34.34 Million | ▼ -306.5% |
| 2015 | -0.14x | $-22.46 Million | $159.32 Million | ▼ -22.2% |
| 2014 | -0.12x | $-12.69 Million | $109.98 Million | — |